Fluidigm | GenomeWeb

Fluidigm

The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.

The partners will co-market the GenomOncology GO Clinical Workbench to interpret data generated using Fluidigm's Juno NGS library prep workflow.

Sales of Helios instruments and genomics analytical consumables were lower than expected, pulling down revenues.

The GenomeWeb Index fell nearly 9 percent in October, doubling back on September's 5 percent gain and underperforming the Dow and the Nasdaq.

The South San Francisco, California-based firm said instrument revenues fell 39 percent, driven by lower-than-average sales of its Helios mass cytometry system.

The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.

Instrument sales, especially the C1 sample prep platform, drove down revenues, though consumables revenue grew 4 percent year over year.

Using a modified single-nuclei RNA sequencing pipeline adapted to deal with postmortem tissue, researchers have uncovered 16 neuronal subtypes.

The firm said it has addressed the doublet issue for its C1 analyzer, and noted that it expects the bulk of revenue growth to come in the second half of the year.

The GenomeWeb Index fell 1 percent in April, outperforming the Nasdaq, but falling significantly short of the performance of the Nasdaq Biotech Index.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.